CD36 and atherosclerosis: Additionally, CD36-targeted LNs exhibited improved EGCG stability and targeted delivery, with reduced liver accumulation relative to native EGCG, positioning it as a promising strategy for macrophage-targeted therapy in atherosclerosis and other macrophage-driven inflammatory conditions [234].